The control group consisted of 170 patients with AODM, selected by year of birth, who were followed up by the endocrinology outpatient clinic between 2012 and 2014. The patients' files were reviewed concerning treatment for diabetes, specifically the use of DPP4i. Both groups were compared for gender, treatment with DPP4i, age, and calendar year of consultation with a 2-sample t test. The χ 2 test and the Wilcoxon rank-sum test were used for categorical and continuous variables, respectively. We compared exposure to DPP4i in both groups with adjustment for confounders such as age, gender, and calendar year of visit with multiple logistic regression models. Effect of exposure was expressed in terms of odds ratios (OR) along with their 95% confidence intervals (CI). Analyses were carried out with Stata software (version 13.1, 2014; StataCorp, College Station, TX, USA). All tests were considered statistically significant at p < 0.05.
An increasing number of reports suggest that inhibitors of the dipeptidyl-peptidase IV (DPP4i) are implicated in the development of bullous pemphigoid (BP) [1] [2] [3] [4] [5] [6] [7] [8] . We investigated BP patients diagnosed in our center (Department of Dermatology and Venereology, Lausanne University Hospital Centre) between January 2007, the year in which the first DPP4i was introduced in Switzerland, and July 2013 to assess whether the use of DPP4i in diabetic patients is potentially related to the development of BP. We searched the database of the laboratory of dermatopathology with the keyword "bullous pemphigoid" between January 2007 and July 2013. We next identified patients with a definite diagnosis of BP with or without adult onset diabetes mellitus (AODM). The diagnosis of BP was based on typical or consistent clinical features, typical or compatible histological findings, and positive immunopathological studies, including direct and indirect immunofluorescence microscopy, and enzyme-linked immunosorbent assays (ELISA) for BP180 and BP230 [9] . If serum was not available for testing, diagnosis was based on the presence of 3 of 4 well-established clinical criteria for BP in patients having linear deposits of C3 and/or IgG along the epidermal basement membrane as detected by direct immunofluorescence microscopy: age >70 years and absence of atrophic scarring, mucosal involvement, and predominant bullous lesions on the neck and head [10] .
The files of diabetic patients with BP were systematically analyzed with regard to (1) antidiabetic treatment(s); (2) comorbidities; (3) history of skin diseases; and (4) chronology between BP diagnosis, treatment, and onset and duration of the DPP4i treatment(s). The association between BP development and the intake of DPP4i for each patient was assessed according to the World Health Organization and Uppsala Monitoring Centre (WHO-UMC) scale, a standardized causality assessment scale of adverse drug reactions [11] , to allow direct comparison with the aforementioned study [1] . 
